The American College of Cardiology (ACC) has partnered with the National Heart Centre Singapore (NHCS) to develop a global diabetes registry. The registry, which supports both diabetes and cardiometabolic research, is the first to globally combine diabetes data and cardiometabolic data.
By combining the NHCS Asian Diabetes Outcomes Registry, which is known as ADORE, with the Diabetes Collaborative Registry, researchers will have access to an unprecedented amount of diabetes data. The researchers are optimistic that the registry can have a significant positive effect on health outcomes for people with diabetes.
“This collaboration has the potential to generate unique, insightful, high-impact research that will likely affect the lives of millions of people,” said Mikhail N. Kosiborod, MD, Cardiologist and Professor of Medicine at Saint Luke’s Mid America Heart Institute and steering committee chair of the Diabetes Collaborative Registry. “Expanding the Diabetes Collaborative Registry into Asia will also expand our ability to track and improve the quality of diabetes and cardiometabolic care for patients, spanning the spectrum of the disease process in primary and specialty care settings – and now spanning the globe.”
The data derived from the partnership will have a range of uses. Researchers will be able to identify patterns in the spread of diabetes in Asian patients, assess the safety and effectiveness of key treatments, understand the level of adherence to diabetes treatment in Asia and identify patterns of the major diabetes complications.
Associate Professor Carolyn Lam, senior consultant with the department of cardiology at NHCS and ADORE principal investigator, said:
“Partnering with the Diabetes Collaborative Registry will expand the impact of ADORE as we combine our expertise and align our data collection to support transnational, comparative, and collaborative diabetes and cardiometabolic research.”
ACC Executive Vice President of Science, Educatio, Quality and Publishing William J. Oetge, believes collaborations like these could be the future of diabetes care.
“Our open, innovative model for collaboration emobides, in the truest sense, a real-world diabetes collaborative, where each partner shares expertise to accelerate our collective vision to transform the future of diabetes care,” Oetgen said. “Through partnerships we can lead the way to drive meaningful change that will have a lasting impact.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…